Characterizing medication management and the role of pharmacists in caring for people living with cystic fibrosis: A work system approach

• Main Authors: Abraham, O. (Author), Braun, A. (Author), Decker, C. (Author), LeMay, S. (Author), Nixon, G. (Author), Szela, L. (Author)
• Format: Article
• Language: English
• Published: Elsevier B.V. 2021
• Subjects: adult; Adult; antifibrotic agent; Article; clinical article; community pharmacist; consultation; cystic fibrosis; Cystic Fibrosis; educational status; ethnicity; failure to thrive; female; gene mutation; health care; health care system; hospitalization; human; Humans; lung function; male; Medication Adherence; medication compliance; medication therapy management; Medication Therapy Management; pancreas enzyme; patient compliance; patient safety; Pharmaceutical Services; pharmacist; Pharmacists; pharmacy (shop); quality of life; semi structured interview; unspecified side effect
• Online Access: View Fulltext in Publisher

 Background: Cystic fibrosis (CF) is an autosomal recessive genetic disease requiring complex, lifelong medication regimens. Given the importance of medication in CF treatment, pharmacists are vital CF care team members in the care of people living with CF (PwCF). Objectives: This study aimed to (1) define patients’ CF medication experiences and educational needs and (2) investigate the CF outpatient clinic and community pharmacist's role in addressing patient challenges. Methods: A work system approach informed by the Systems Engineering Initiative for Patient Safety (SEIPS) model was used to characterize knowledge and perception of CF medication regimens, educational modalities, and pharmacist interactions for PwCF. Semistructured interviews were conducted with adults living with CF at a CF center clinic. Data analyses identified relationships between the themes in the data and 4 SEIPS work system domains: tasks, tools and technology, person, and environment. Results: Thirty PwCF interviews highlighted 4 themes regarding health care experiences: (1) medication use experience, (2) medication education needs, (3) disease experience, and (4) pharmacist and pharmacy interactions. Patients reported complex medication regimens leading to challenges with medication adherence, although the benefit of treatment was recognized. Although a high level of disease-state knowledge was identified among the participants, PwCF desired to learn about CF medication benefits and adverse effects through credible sources using multiple modalities. Many reported a benefit of pharmacist involvement in their care. Conclusion: Pharmacists are well-positioned to support PwCF in adherence, medication regimen management, and medication education. Opportunities exist for growth in these supportive roles of a pharmacist in both community and outpatient clinic settings. © 2021 American Pharmacists Association®